Ultragenyx Pharmaceutical IncNASDAQ:RARE
- LAST PRICE40.5200
- TODAY'S CHANGE (%)0.6700 (1.6813%)
- Bid / Lots40.4400/ 2
- Ask / Lots40.5200/ 2
- Open / Previous Close39.8800 / 39.8500
- Day Range
- 52 Week Range
- Volume448,504
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RARE |
|---|---|---|
| 09:32 ET | 2367 | 39.88 |
| 09:34 ET | 700 | 39.83 |
| 09:36 ET | 200 | 39.825 |
| 09:38 ET | 900 | 39.81 |
| 09:39 ET | 200 | 40.15 |
| 09:41 ET | 1399 | 39.81 |
| 09:43 ET | 200 | 39.815 |
| 09:45 ET | 300 | 39.99 |
| 09:48 ET | 100 | 39.99 |
| 09:50 ET | 1036 | 39.895 |
| 09:52 ET | 800 | 40 |
| 09:54 ET | 41598 | 40.11 |
| 09:56 ET | 100 | 40.19 |
| 09:57 ET | 400 | 40.49 |
| 09:59 ET | 327 | 40.36 |
| 10:01 ET | 900 | 40.5 |
| 10:03 ET | 760 | 40.41 |
| 10:06 ET | 37253 | 40.46 |
| 10:08 ET | 13742 | 40.445 |
| 10:10 ET | 32891 | 40.57 |
| 10:12 ET | 9067 | 40.69 |
| 10:14 ET | 12112 | 40.735 |
| 10:15 ET | 9428 | 40.565 |
| 10:17 ET | 4006 | 40.595 |
| 10:19 ET | 1200 | 40.52 |
| 10:21 ET | 1968 | 40.61 |
| 10:24 ET | 6100 | 40.705 |
| 10:26 ET | 1600 | 40.75 |
| 10:28 ET | 2708 | 40.56 |
| 10:30 ET | 4311 | 40.55 |
| 10:32 ET | 1090 | 40.55 |
| 10:33 ET | 15779 | 40.325 |
| 10:35 ET | 1100 | 40.405 |
| 10:37 ET | 1413 | 40.385 |
| 10:39 ET | 800 | 40.37 |
| 10:42 ET | 889 | 40.34 |
| 10:44 ET | 1029 | 40.345 |
| 10:46 ET | 1394 | 40.41 |
| 10:48 ET | 800 | 40.42 |
| 10:50 ET | 600 | 40.3575 |
| 10:51 ET | 1300 | 40.51 |
| 10:53 ET | 12210 | 40.35 |
| 10:55 ET | 800 | 40.425 |
| 10:57 ET | 100 | 40.34 |
| 11:00 ET | 2471 | 40.41 |
| 11:02 ET | 713 | 40.4886 |
| 11:04 ET | 700 | 40.43 |
| 11:06 ET | 1400 | 40.5 |
| 11:08 ET | 3090 | 40.45 |
| 11:11 ET | 728 | 40.38 |
| 11:13 ET | 400 | 40.19 |
| 11:15 ET | 100 | 40.12 |
| 11:18 ET | 200 | 40.175 |
| 11:20 ET | 100 | 40.23 |
| 11:22 ET | 100 | 40.24 |
| 11:24 ET | 700 | 40.34 |
| 11:26 ET | 1512 | 40.35 |
| 11:27 ET | 1400 | 40.29 |
| 11:29 ET | 2778 | 40.29 |
| 11:31 ET | 331 | 40.41 |
| 11:33 ET | 100 | 40.405 |
| 11:36 ET | 1200 | 40.35 |
| 11:38 ET | 300 | 40.32 |
| 11:40 ET | 300 | 40.34 |
| 11:42 ET | 200 | 40.27 |
| 11:44 ET | 321 | 40.31 |
| 11:45 ET | 300 | 40.38 |
| 11:49 ET | 295 | 40.45 |
| 11:51 ET | 941 | 40.48 |
| 11:54 ET | 100 | 40.48 |
| 11:56 ET | 1300 | 40.51 |
| 11:58 ET | 32275 | 40.45 |
| 12:00 ET | 847 | 40.42 |
| 12:02 ET | 3244 | 40.46 |
| 12:03 ET | 6164 | 40.425 |
| 12:05 ET | 1100 | 40.3 |
| 12:07 ET | 1568 | 40.295 |
| 12:12 ET | 794 | 40.33 |
| 12:14 ET | 709 | 40.35 |
| 12:16 ET | 970 | 40.35 |
| 12:20 ET | 344 | 40.335 |
| 12:21 ET | 400 | 40.35 |
| 12:23 ET | 300 | 40.355 |
| 12:25 ET | 863 | 40.355 |
| 12:27 ET | 330 | 40.37 |
| 12:30 ET | 8883 | 40.425 |
| 12:32 ET | 100 | 40.48 |
| 12:34 ET | 1789 | 40.465 |
| 12:36 ET | 1143 | 40.47 |
| 12:38 ET | 1949 | 40.465 |
| 12:39 ET | 925 | 40.395 |
| 12:41 ET | 800 | 40.46 |
| 12:43 ET | 2014 | 40.455 |
| 12:45 ET | 1105 | 40.43 |
| 12:48 ET | 1525 | 40.405 |
| 12:50 ET | 1439 | 40.34 |
| 12:52 ET | 1301 | 40.4 |
| 12:54 ET | 787 | 40.4 |
| 12:56 ET | 775 | 40.35 |
| 12:57 ET | 300 | 40.39 |
| 12:59 ET | 600 | 40.38 |
| 01:01 ET | 2511 | 40.49 |
| 01:03 ET | 1018 | 40.48 |
| 01:06 ET | 900 | 40.51 |
| 01:08 ET | 6550 | 40.48 |
| 01:10 ET | 6444 | 40.53 |
| 01:12 ET | 900 | 40.51 |
| 01:14 ET | 2110 | 40.43 |
| 01:15 ET | 1256 | 40.41 |
| 01:17 ET | 259 | 40.48 |
| 01:19 ET | 1708 | 40.465 |
| 01:21 ET | 4335 | 40.52 |
Jun 20, 2024
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Thursday Jun 20, 2024 by Dow Jones
4:30PM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 13, 2024
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants, from 8:49PM ET on Thursday Jun 13, 2024 by Dow Jones
8:49PM ET on Thursday Jun 13, 2024 by Dow JonesDJ Ultragenyx Shares Slip Premarket on Planned Stock Offering, from 6:04AM ET on Thursday Jun 13, 2024 by Dow Jones
6:04AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
DJ Ultragenyx Pharmaceuticals to Seek Accelerated Approval of Genetic Disease Treatment, from 4:11PM ET on Wednesday Jun 12, 2024 by Dow Jones
4:11PM ET on Wednesday Jun 12, 2024 by Dow JonesUltragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, from 4:05PM ET on Wednesday Jun 12, 2024 by Dow Jones
4:05PM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ultragenyx Pharmaceutical Inc | 3.7B | -5.0x | --- |
Guardant Health Inc | 3.6B | -7.4x | --- |
Amicus Therapeutics Inc | 2.9B | -19.7x | --- |
Tempus AI Inc | 4.1B | -15.1x | --- |
Axsome Therapeutics Inc | 3.8B | -12.1x | --- |
Denali Therapeutics Inc | 3.2B | -22.6x | --- |
Company Information
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Contact Information
- Headquarters
- 60 Leveroni CtNOVATO, CA, United States 94949-5746
- Phone
- 415-483-8800
- Fax
- 415-483-8810
Executives
- Independent Chairman of the Board
- Daniel Welch
- President, Chief Executive Officer, Director
- Emil Kakkis
- Chief Financial Officer, Executive Vice President, Corporate Strategy
- Howard Horn
- Executive Vice President, Chief Technical Operations Officer and Gene Therapy Operations
- Dennis Huang
- Executive Vice President, Chief Legal Officer, General Counsel
- Karah Parschauer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7B |
|---|---|
Revenue (TTM) | $442.6M |
Shares Outstanding | 93.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.55 |
EPS | $-8.02 |
Book Value | $3.35 |
P/E Ratio | -5.0x |
Price/Sales (TTM) | 8.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -131.15% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
